Antiarrhythmika
Begutachtet von Dr Toni Hazell, FRCGPZuletzt aktualisiert von Dr Hayley Willacy, FRCGP Zuletzt aktualisiert 15. Juni 2023
Erfüllt die redaktionelle Richtlinien
- HerunterladenHerunterladen
- Teilen
- Language
- Diskussion
- Ask Patient
- Audio-Version
- Zu bevorzugten Quellen bei Google hinzufügen
Medizinische Fachkräfte
Fachartikel sind für die Nutzung durch Gesundheitsfachkräfte konzipiert. Sie werden von britischen Ärzten verfasst und basieren auf Forschungsergebnissen, britischen und europäischen Richtlinien. Möglicherweise finden Sie einen unserer Gesundheitsartikel nützlicher.
Arrhythmias are due to a disturbance of the electrical impulses which regulate the heart. The heart may beat too slowly (bradycardia), too quickly (tachycardia) or in an irregular way. The normal heart rate is between 60-100 beats per minute for adults.
Management of an arrhythmia requires precise diagnosis of the type of arrhythmia. Electrocardiography is essential.1
Underlying causes (eg, Herzinfarkt, Herzversagen, Thyreotoxikose, alcohol abuse) require appropriate treatment.
Classifying anti-arrhythmic drugs
Anti-arrhythmic drugs can be classified clinically into:
Those that act on supraventricular arrhythmias - eg, adenosine, verapamil, cardiac glycosides and beta-blockers.
Those that act on both supraventricular and ventricular arrhythmias - eg, amiodarone, beta-blockers, disopyramide, flecainide, and propafenone.
Those that act on ventricular arrhythmias - eg, lidocaine and moracizine.
Anti-arrhythmic drugs can also be classified according to their effects on the electrical behaviour of myocardial cells during activity but this classification is of less clinical use. The Vaughan Williams classification is based on the movement of ions (sodium, potassium, calcium) into heart cells:
Class I: membrane-stabilising (Ia) procainamide, disopyramide, (Ib) lidocaine, (Ic) flecainide.
Class II: reduce adrenergic input - Betablocker.
Class IV: calcium influx blockers - eg, verapamil (but not dihydropyridines).
Sotalol has both Class II and Class III actions. Digoxin does not fit into this classification.
Präsentation
Arrhythmias can present as Herzklopfen or with the symptoms of reduced cardiac outflow: chest pain, dyspnoea, dizziness or blackouts (typically with a rapid recovery).
The history from an observer can be invaluable in distinguishing an arrhythmia from a cerebral event or convulsion.
Arrhythmias range in severity from a minor inconvenience to a potentially fatal problem. They are common, particularly in the elderly. They can have a profound effect on quality of life. Appropriate information and support can relieve psychological as well as physical problems.
Main types of arrhythmias
Diagnose1 2
Accurate diagnosis of a suspected arrhythmia requires a prompt recording and archiving of a 12-Kanal-EKG. Even if symptoms have subsided, this improves the chance of accurate diagnosis and treatment:
High-resolution ECG averages signals to reduce background noise and can reveal areas of slow conduction.
Supraventricular (atrial and atrioventricular (AV) node initiated) fast rhythms which are transmitted by the normal conducting pathway are generally narrow complex tachycardias.
Tachyarrhythmias which either originate from the ventricle, or are atrial rhythms but are aberrantly propagated through the ventricular muscle rather than completely through the conducting pathway, have wider QRS complexes and are called broad complex tachycardias.
Ambulatory ECG monitoring over 24-48 hours allows analysis of heart rate variability and matching of arrhythmia to symptoms, but is only useful if the patient has symptoms frequently over a two-day period. If the frequency is less than that, a 5-7 day ECG will be more appropriate. More detailed electrophysiological studies require cardiac catheterisation.
All causes and effects of any arrhythmia must be thoroughly evaluated. This will depend on the particular arrhythmia and clinical context but may include:
Blood tests - eg, renal function, electrolytes, TFTs.
Echocardiogram - structural and functional heart abnormalities or detection of intracardiac thrombus.
Exercise tolerance testing.
Principles of pharmacological treatment
Deciding on appropriate therapy depends on distinguishing supraventricular von ventricular rhythms. This is not always easy and expert advice should be sought if there is any doubt.
All anti-arrhythmic drugs have potentially serious side-effects. They may worsen or provoke arrhythmias in certain circumstances, such as hypokalaemia. Close monitoring is therefore essential.
The negative inotropic effects of anti-arrhythmic drugs tend to be additive when more than one drug is required. Therefore special care should be taken if two or more are used, especially if myocardial function is impaired.
Other management options available
Implantable cardioverter defibrillators can be used. A combination of one drug plus an implantable device is also appropriate in some situations. Ablation therapy provides an alternative for treating certain cardiac arrhythmias.3
Exklusive Updates für medizinisches Fachpersonal
Bleiben Sie informiert mit den neuesten klinischen Updates, professionellen Einblicken und evidenzbasierten Leitlinien. Der Patient Pro-Newsletter stellt wesentliche Inhalte für Gesundheitsfachkräfte zusammen – direkt in Ihren Posteingang geliefert.
Durch das Abonnieren akzeptieren Sie unsere Datenschutzrichtlinie. Sie können sich jederzeit abmelden. Wir verkaufen Ihre Daten niemals.
Weiterführende Lektüre und Referenzen
- Brugada J, Katritsis DG, Arbelo E, et al; 2019 ESC-Leitlinien für das Management von Patienten mit supraventrikulärer Tachykardie. Die Task Force für das Management von Patienten mit supraventrikulärer Tachykardie der Europäischen Gesellschaft für Kardiologie (ESC). Eur Heart J. 2020 Feb 1;41(5):655-720. doi: 10.1093/eurheartj/ehz467.
- Chhabra L, Goyal A, Benham MD; Wolff-Parkinson-White Syndrome.
- Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al; 2022 ESC-Leitlinien für das Management von Patienten mit ventrikulären Arrhythmien und die Prävention des plötzlichen Herztodes. Eur Heart J. 2022 Okt 21;43(40):3997-4126. doi: 10.1093/eurheartj/ehac262.
- Herzklopfen; NICE CKS, Februar 2026 (nur für UK-Zugang)
- Moulton KP, Bhutta BS, Mullin JC; Evaluation of Suspected Cardiac Arrhythmia.
- Percutaneous (non-thoracoscopic) epicardial catheter radiofrequency ablation for ventricular tachycardia; NICE Interventional Procedure Guideline, March 2009
Über den RezensentenVollständige Biografie anzeigen

Dr Toni Hazell, FRCGP
MBBS, BSc, FRCGP, DFSRH, Dip GU med, DRCOG, DCH (London, UK, 2000)
Dr. Toni Hazell hat ihren Abschluss an der St. Mary’s Hospital Medical School gemacht und ihr VTS am Northwick Park Hospital absolviert.
Artikelverlauf
Artikel auch verfügbar in Englisch, Deutsch, Spanisch, Französisch, Italienisch, Portugiesisch, Hindi, Hebräisch, Arabisch, und Schwedisch.
Nächste Überprüfung fällig: 12. Mai 2028
15. Juni 2023 | Neueste Version
Mehr zu Herz-Kreislauf-Erkrankungen
- Kardiovaskuläre Risikobewertung
- Cheyne-Stokes und abnorme Atemmuster
- Cholesterinsenkende Sterole und Stanole
- Tiefe Venenthrombose
- Diuretika
- Ebstein-Anomalie
- Belastungstest
- Hypertonie
- Behandlung von Bluthochdruck
- Hypotonie
- Mitralklappenprolaps
- Moyamoya-Krankheit
- Organspende
- Portale Hypertonie
- Sarkoidose
- Sick-Sinus-Syndrom
- Subarachnoidalblutung
- Subclavian-Steal-Phänomen
- Transposition der großen Arterien


